Business
Positive decision on Feraccru®'s process patent
Positive decision on Feraccru®'s process patent.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 9328S Shield Therapeutics PLC 14 March 2019 \n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\n \nEuropean Patent Office reaches positive decision on Feraccru®'s process patent \n \nLondon, UK, 14 March 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that, further to Shield's announcement on 24 January 2019 and in relation to the Group's patent #2 668 175, which covers a \"Process for preparing an iron hydroxypyrone\", the Opposition Division of the European Patent Office (EPO) has today decided in favour of Shield.\n \nThe decision by the EPO, which was reached having taken into account Shield's first and preferred minor amendment, follows a hearing in relation to the opposition that had been filed against the patent by a third party. This means that the patent as amended and the invention to which it relates meet the requirements of the European Patent Convention and they will continue to provide protection to Feraccru® through to 2032. \n \nCustomary rights of appeal apply to the third-party opposition and Shield will continue to proactively and robustly defend its intellectual property.\n \n- Ends -\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nCarl Sterritt, Chief Executive Officer\n\n\n+44 (0)20 7186 8500\n\n\n\n\nTim Watts, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Advisor and Joint Broker\n\n\n\n\n\n\n\nLiberum Capital Limited\n\n\n\n\n\n\n\nChristopher Britton/Steve Pearce\n\n\n+44 (0)20 3100 2222\n\n\n\n\n\n\n\n\n\n\n\n\nJoint Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Dr Christopher Golden\n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial PR & IR Advisor\n\n\n\n\n\n\n\nWalbrook PR\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Helen Cresswell\n\n\n+44 (0)7980 541 893 / +44 (0)7841 917 679\n\n\n\n \n \nAbout Shield Therapeutics plc\nShield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose ...